# Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

> **NCT00852540** · PHASE3 · COMPLETED · sponsor: **Stiefel, a GSK Company** · enrollment: 410 (actual)

## Conditions studied

- Skin Infections, Bacterial

## Interventions

- **DRUG:** Retpamulin Ointment, 1%
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT00852540
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-07
- **Final completion:** 2010-09
- **Target enrollment:** 410 (ACTUAL)
- **Last updated:** 2017-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00852540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00852540, "Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00852540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*